CAMBRIDGE, Mass. and VANCOUVER, British Columbia and BASEL, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: ...

Scientists at Colossal Biosciences may be a few steps closer to resurrecting a long-extinct carnivorous marsupial known as ...

Gene-editing therapies—techniques that modify DNA to treat or prevent disease—have the potential to transform the field of ...

CRISPR genome editing is revolutionizing medicine. Rapid market growth, fueled by startups and new therapies, brings ethical ...

UCSB Arts & Lectures and the Cancer Foundation of Santa Barbara host the Nobel Prize–winning biochemist for a talk on CRISPR ...

While the Nobel-winning genome-editing technology CRISPR holds great promise, Duke’s Center for Advanced Genomic Technologies ...

Colossal Biosciences, which intends to create proxy species of the woolly mammoth, dodo, and Tasmanian tiger, claims it has ...

Discover how genetic mutations, like BRCA1 and BRCA2, impact cancer risk and personalized treatment strategies.

Two public companies focused on RNA editing therapies, Korro Bio and ProQR, enjoyed impressive stock surges powered by their best-ever one day gains; their share prices lifted by Wave Life Sciences ...

Wave Life Sciences' alpha-1 antitrypsin deficiency candidate WVE-006 succeeded in the first-ever clinical demonstration of ...

HuidaGene Therapeutics ("HuidaGene"), a global clinical-stage biotechnology company pioneering CRISPR-based programmable genome medicines, today announced the appointment of Dr. TJ Cradick as Chief ...